Document is current
Any future updates will be listed below
-
Authors
Xiong, Chengjie
Luo, Jingqin https://orcid.org/0000-0003-2759-3072
Wolk, David A.
Shaw, Leslie M.
Roberson, Erik D. https://orcid.org/0000-0002-1810-9763
Murchison, Charles F.
Henson, Rachel L.
Benzinger, Tammie L. S. https://orcid.org/0000-0002-8114-0552
Bui, Quoc
Agboola, Folasade
Grant, Elizabeth
Gremminger, Emily N.
Moulder, Krista L.
Geldmacher, David S.
Clay, Olivio J.
Babulal, Ganesh
Cruchaga, Carlos https://orcid.org/0000-0002-0276-2899
Holtzman, David M. https://orcid.org/0000-0002-3400-0856
Bateman, Randall J. https://orcid.org/0000-0002-7729-1702
Morris, John C.
Schindler, Suzanne E. https://orcid.org/0000-0002-1680-1465
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01 AG070941, R01 AG067505, P30 AG072979, P20 AG068024, P30 AG066444, P01 AG026276, P01 AG003991)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Cure Alzheimer's Fund
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
- License Information
-
More Information
Article History
Received: 20 December 2023
Accepted: 21 June 2024
First Online: 2 July 2024
Competing interests
: D.A.W. has served as a paid consultant for Eli Lilly, GE Healthcare and Qynapse, and serves on a DSMB for Functional Neuromodulation. E.D.R. serves on a data monitoring committee for Eli Lilly. T.L.S.B. participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly and Company, Biogen, Eisai, Janssen, and Roche. D.S.G. participates as a site investigator in clinical trials sponsored by Biogen and Janssen. He serves as a consultant to Eisai, Lilly, and Roche. DMH and RJB co-founded and have equity in C<sub>2</sub>N Diagnostics. D.M.H. serves on the scientific advisory board of C2N Diagnostics, Genentech, Denali, Cajal Neurosciences, and Asteroid. S.E.S. has served on advisory boards for Eisai. Washington University has a financial interest in C<sub>2</sub>N Diagnostics and may financially benefit if the company is successful in marketing its product(s) that is/are related to this research. The other authors declare no competing interests.
